| Year |
Citation |
Score |
| 2020 |
Polepally AR, Ng JW, Salem AH, Dufek MB, Parikh A, Carter DC, Kamradt K, Mostafa NM, Shebley M. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist. Journal of Clinical Pharmacology. PMID 33045114 DOI: 10.1002/Jcph.1689 |
0.407 |
|
| 2019 |
Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, Noertersheuser P, Gibbs MA, Mostafa NM. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis. Clinical Pharmacokinetics. PMID 31749075 DOI: 10.1007/S40262-019-00840-7 |
0.403 |
|
| 2019 |
Khatri A, Suleiman AA, Polepally AR, Othman AA. Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase 2 and 3 Trials in Psoriasis Patients. Clinical Pharmacology and Therapeutics. PMID 31355921 DOI: 10.1002/Cpt.1594 |
0.332 |
|
| 2019 |
Poordad F, Sedghi S, Pockros PJ, Ravendhran N, Reindollar R, Lucey MR, Epstein M, Bank L, Bernstein D, Trinh R, Krishnan P, Polepally AR, Unnebrink K, Martinez M, Nelson DR. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. Journal of Viral Hepatitis. PMID 30980576 DOI: 10.1111/Jvh.13109 |
0.435 |
|
| 2018 |
Polepally AR, Brundage RC, Remmel RP, Leppik IE, Pennell PB, White JR, Ramsay RE, Kistner BM, Birnbaum AK. Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age. Epilepsia. PMID 30101556 DOI: 10.1111/Epi.14519 |
0.516 |
|
| 2018 |
Winzenborg I, Nader A, Polepally AR, Liu M, Degner J, Klein CE, Mostafa NM, Noertersheuser P, Ng J. Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis. Clinical Pharmacokinetics. PMID 29476499 DOI: 10.1007/S40262-018-0629-6 |
0.329 |
|
| 2017 |
Polepally AR, Wang H, Marroum PJ, Minocha M, Hosmane B, Khatri A, Mensing S, Podsadecki TJ, Cohen DE, Awni WM, Menon RM. Application of Exposure-Response Analyses to Establish the Pharmacodynamic Similarity of a Once-Daily Regimen to an Approved Twice-Daily Dosing Regimen for the Treatment of HCV Infection. The Aaps Journal. PMID 28685397 DOI: 10.1208/S12248-017-0115-3 |
0.465 |
|
| 2017 |
Menon RM, Polepally AR, Khatri A, Awni WM, Dutta S. Clinical Pharmacokinetics of Paritaprevir. Clinical Pharmacokinetics. PMID 28236252 DOI: 10.1007/S40262-017-0520-X |
0.501 |
|
| 2016 |
Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in hepatitis C virus genotype 1 infection: analysis of 6 phase 3 trials. British Journal of Clinical Pharmacology. PMID 27662429 DOI: 10.1111/Bcp.13138 |
0.426 |
|
| 2016 |
Polepally AR, Badri PS, Parikh A, Rodrigues L, Da Silva-Tillmann BA, Mensing S, Podsadecki TJ, Awni WM, Dutta S, Menon RM. Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir, and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials. Antiviral Therapy. PMID 27584548 DOI: 10.3851/Imp3079 |
0.371 |
|
| 2016 |
Gopalakrishnan SM, Polepally AR, Mensing S, Khatri A, Menon RM. Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. Clinical Pharmacokinetics. PMID 27314261 DOI: 10.1007/S40262-016-0423-2 |
0.44 |
|
| 2016 |
Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir. Clinical Pharmacology in Drug Development. 5: 269-277. PMID 27310328 DOI: 10.1002/Cpdd.246 |
0.393 |
|
| 2016 |
Polepally AR, Badri PS, Eckert D, Mensing S, Menon RM. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection. European Journal of Drug Metabolism and Pharmacokinetics. PMID 27165046 DOI: 10.1007/S13318-016-0341-6 |
0.421 |
|
| 2016 |
Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical Pharmacokinetics. PMID 27000758 DOI: 10.1007/S40262-016-0385-4 |
0.475 |
|
| 2016 |
Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, Menon RM. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clinical Pharmacokinetics. PMID 26895022 DOI: 10.1007/S40262-016-0373-8 |
0.421 |
|
| 2015 |
Mensing S, Polepally AR, König D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The Aaps Journal. PMID 26597291 DOI: 10.1208/S12248-015-9846-1 |
0.495 |
|
| 2015 |
Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, et al. Sustained Virologic Response of 100% in HCV Genotype 1b Patients with Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir for 12 Weeks. Journal of Hepatology. PMID 26476290 DOI: 10.1016/J.Jhep.2015.10.005 |
0.423 |
|
| 2015 |
Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir/Ritonavir (2D Regimen). Antimicrobial Agents and Chemotherapy. PMID 26459906 DOI: 10.1128/Aac.01778-15 |
0.47 |
|
| 2015 |
Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clinical Pharmacokinetics. PMID 26330025 DOI: 10.1007/S40262-015-0317-8 |
0.424 |
|
| 2015 |
Polepally AR, Remmel RP, Brundage RC, Leppik IE, Rarick JO, Ramsay RE, Birnbaum AK. Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. Journal of Clinical Pharmacology. 55: 1101-8. PMID 25903807 DOI: 10.1002/Jcph.522 |
0.534 |
|
| 2015 |
Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, Felizarta F, McGovern B, King M, Polepally AR, Cohen DE. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology. 63: 364-369. PMID 25839406 DOI: 10.1016/J.Jhep.2015.03.029 |
0.46 |
|
| 2015 |
Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. Journal of Hepatology. 63: 20-9. PMID 25646891 DOI: 10.1016/J.Jhep.2015.01.026 |
0.45 |
|
| 2015 |
Mensing S, Sharma S, Eckert D, Polepally A, Khatri A, Podsadecki T, Awni W, Menon R, Dutta S. P0820 : Pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection in phase 3 studies Journal of Hepatology. 62: S644. DOI: 10.1016/S0168-8278(15)31023-0 |
0.377 |
|
| 2014 |
Polepally AR, Pennell PB, Brundage RC, Stowe ZN, Newport DJ, Viguera AC, Ritchie JC, Birnbaum AK. MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION. Annals of Clinical and Translational Neurology. 1: 99-106. PMID 24883336 DOI: 10.1002/Acn3.29 |
0.504 |
|
| Show low-probability matches. |